269 related articles for article (PubMed ID: 25035208)
21. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer.
Bassi MC; Turri L; Sacchetti G; Loi G; Cannillo B; La Mattina P; Brambilla M; Inglese E; Krengli M
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1423-6. PubMed ID: 17931795
[TBL] [Abstract][Full Text] [Related]
22. Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on (18)F-FDG-PET/CT resembling an early recurrence of Hodgkin's Lymphoma.
Fallanca F; Picchio M; Crivellaro C; Mapelli P; Samanes Gajate AM; Sabattini E; Gianolli L; Messa C
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):207-9. PubMed ID: 22980128
[TBL] [Abstract][Full Text] [Related]
23. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
[TBL] [Abstract][Full Text] [Related]
24. Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD.
Albano D; Patti C; Matranga D; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2018 Jun; 103():90-98. PubMed ID: 29803392
[TBL] [Abstract][Full Text] [Related]
25. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines.
Girinsky T; Specht L; Ghalibafian M; Edeline V; Bonniaud G; Van Der Maazen R; Aleman B; Paumier A; Meijnders P; Lievens Y; Noordijk E; Poortmans P;
Radiother Oncol; 2008 Aug; 88(2):202-10. PubMed ID: 18555548
[TBL] [Abstract][Full Text] [Related]
26. Risk- and response-adapted strategies for the management of Hodgkin lymphoma.
Remer M; Johnson PW
Chin Clin Oncol; 2015 Mar; 4(1):13. PubMed ID: 25841720
[TBL] [Abstract][Full Text] [Related]
27. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
Hutchings M; Loft A; Hansen M; Berthelsen AK; Specht L
Eur J Haematol; 2007 Mar; 78(3):206-12. PubMed ID: 17253974
[TBL] [Abstract][Full Text] [Related]
29. [Evolution in 18F-FDG-PET of a case of Hodgkin disease, nodular sclerosis variety, after treatment and autotrasplant].
Sánchez-Salmón A; Barandela J; Garrido M; Ciobotaru AB; Albo C; Ruibal A
Rev Esp Med Nucl; 2007; 26(3):165-8. PubMed ID: 17524311
[TBL] [Abstract][Full Text] [Related]
30. 18F-fluorodeoxyglucose positron emission tomography/computed tomography-based radiotherapy target volume definition in non-small-cell lung cancer: delineation by radiation oncologists vs. joint outlining with a PET radiologist?
Hanna GG; Carson KJ; Lynch T; McAleese J; Cosgrove VP; Eakin RL; Stewart DP; Zatari A; O'Sullivan JM; Hounsell AR
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1040-51. PubMed ID: 20350798
[TBL] [Abstract][Full Text] [Related]
31. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.
Ashamalla H; Rafla S; Parikh K; Mokhtar B; Goswami G; Kambam S; Abdel-Dayem H; Guirguis A; Ross P; Evola A
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1016-23. PubMed ID: 15979817
[TBL] [Abstract][Full Text] [Related]
32. Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study.
Brændengen M; Hansson K; Radu C; Siegbahn A; Jacobsson H; Glimelius B
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e439-45. PubMed ID: 21641122
[TBL] [Abstract][Full Text] [Related]
33. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma.
Paumier A; Ghalibafian M; Beaudre A; Ferreira I; Pichenot C; Messai T; Lessard NA; Lefkopoulos D; Girinsky T
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):199-205. PubMed ID: 21481723
[TBL] [Abstract][Full Text] [Related]
34. Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.
Povoski SP; Hall NC; Murrey DA; Wright CL; Martin EW
BMC Cancer; 2015 May; 15():378. PubMed ID: 25953144
[TBL] [Abstract][Full Text] [Related]
35. Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma.
Chiaravalloti A; Danieli R; Abbatiello P; Di Pietro B; Travascio L; Cantonetti M; Guazzaroni M; Orlacchio A; Simonetti G; Schillaci O
Eur J Nucl Med Mol Imaging; 2014 Jun; 41(6):1123-32. PubMed ID: 24562647
[TBL] [Abstract][Full Text] [Related]
36. Can We Predict Bleomycin Toxicity with PET-CT?
Beyhan Sagmen S; Comert S; Turan Erkek E; Küçüköz Uzun A; Doğan C; Yılmaz G; Kıral N; Fidan A; Yılmaz Haksal Ç; Torun Parmaksız E
Acta Haematol; 2019; 142(3):171-175. PubMed ID: 31454795
[TBL] [Abstract][Full Text] [Related]
37. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):324-32. PubMed ID: 20646867
[TBL] [Abstract][Full Text] [Related]
38. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
[TBL] [Abstract][Full Text] [Related]
39. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
[TBL] [Abstract][Full Text] [Related]
40. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
